Sientra third quarter losses worse than analysts expected

You are here: Home > Biotech > Current Article

Sientra’s third quarter losses worse than analysts expected

By Staff Report / Tuesday, November 6th, 2018 / Comments Off on Sientra’s third quarter losses worse than analysts expected

Sales at Goleta breast implant manufacturer Sientra rose 72 percent to $16.9 million, according to a Nov. 6 report, but net losses mounted to $20.5 million for the third quarter, or 74 cents per share. The earnings missed analyst expectations of a 67 cent loss per share. The company reported that miraDry sales nearly tripled…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.